| Old Articles: <Older 8401-8410 Newer> |
|---|
 |
The Motley Fool
July 14, 2005
Matt Thurmond |
Wolverine Walks the Walk The shoe company's growth is slowing, but it can still provide comfortable returns over the long run.   |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business. |
The Motley Fool
July 14, 2005
Tim Beyers |
Fool by Numbers: Knight Ridder Q2 2005 The media company released second quarter earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... etc. |
The Motley Fool
July 14, 2005
Tim Beyers |
Fool by Numbers: Yum! Brands Q2 2005 The fast food company released second quarter earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
July 14, 2005
Seth Jayson |
Harder on Harley Harley's road may be bumpier than the happy headlines imply. Could it be the stock's really not that cheap? |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
A Health-Care Sequoia Growth will slow someday for United Health, but that day hasn't come just yet. Investors, take note. |
The Motley Fool
July 14, 2005
Tim Beyers |
Fool by Numbers: Datalink Q2 2005 The data storage company released second quarter earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
Dueling Fools: Protein Design Labs Bear Rebuttal By looking at the price-to-book ratio, you can get a sense of just how much optimism is baked into a biotech stock. Offer the stock at $18 or below, and we'll talk. Until then, the risk-benefit analysis swings more to "risk". |
The Motley Fool
July 14, 2005
Charly Travers |
Dueling Fools: Protein Design Labs Bull Rebuttal This biotech's tomorrow is coming today. The company is a clear buy at its current market cap near $2 billion. |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great." |
| <Older 8401-8410 Newer> Return to current articles. |
